HC Wainwright Begins Coverage on Zevra Therapeutics (NASDAQ:ZVRA)

HC Wainwright started coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA - Free Report) in a research report released on Wednesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $26.00 target price on the stock.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group lifted their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 target price on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Guggenheim lifted their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, March 13th. Finally, JMP Securities set a $18.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Zevra Therapeutics has an average rating of "Buy" and a consensus target price of $23.14.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA traded up $0.29 during mid-day trading on Wednesday, reaching $9.70. 1,006,572 shares of the company were exchanged, compared to its average volume of 682,347. The stock has a market capitalization of $530.12 million, a P/E ratio of -5.10 and a beta of 1.97. The company has a quick ratio of 2.93, a current ratio of 3.02 and a debt-to-equity ratio of 1.46. The company's 50-day simple moving average is $8.52 and its 200-day simple moving average is $8.08. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $10.03.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. The firm had revenue of $20.40 million for the quarter, compared to analysts' expectations of $16.96 million. During the same period in the prior year, the firm earned ($0.40) EPS. As a group, research analysts predict that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new position in Zevra Therapeutics in the fourth quarter valued at approximately $53,000. GAMMA Investing LLC increased its holdings in Zevra Therapeutics by 20,564.1% in the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock valued at $60,000 after purchasing an additional 8,020 shares during the period. Strs Ohio bought a new position in Zevra Therapeutics during the 1st quarter worth $125,000. Squarepoint Ops LLC grew its position in shares of Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after buying an additional 4,384 shares during the last quarter. Finally, ProShare Advisors LLC bought a new stake in shares of Zevra Therapeutics in the 4th quarter valued at about $145,000. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.